TITLE:
STA-5326 in Crohn's Disease Patients

CONDITION:
Crohn's Disease

INTERVENTION:
STA-5326

SUMMARY:

      The purpose of this study is to determine the safety and tolerability of STA-5326 given once
      daily or twice daily to Crohn's Disease patients with moderate disease.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to 65 Years
Criteria:

        Inclusion Criteria:

          -  Patients 18-65 years old

          -  Crohn's Disease for 6 months

          -  CDAI scores between 220-450

          -  +/- 5-ASA, stable dose for > 2 weeks

          -  +/- Corticosteroids, less than or equal to 40 mg per day with a stable dose for 2
             weeks

          -  +/- Infliximab with no treatment within 4 weeks

          -  +/- 6-Mercaptopurine, with a stable dose for 8 weeks

          -  +/- Antibiotics, with a stable dose for 2 weeks

        Exclusion Criteria:

          -  Patients who have had methotrexate, cyclosporine, or other experimental drug within 3
             months of screening

          -  Pregnancy, breast feeding

          -  History of total proctocolectomy with stoma. Previous ileocolectomy would not be a
             contraindication to the study

          -  Bowel obstruction

          -  Surgical bowel resection within 90 days

          -  Total parenteral nutrition (TPN), CYA, tacrolimus
      
